☆ 4.7 Article

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Related references

Note: Only part of the references are listed.

Review Multidisciplinary Sciences

Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer

Claire Shao et al.

Summary: TNBC is a heterogeneous disease characterized by lack of hormone receptor expression, with high recurrence and distant metastasis rates. Targeting breast cancer stem-like cells is an effective strategy for preventing metastatic spread and enhancing sensitivity to chemotherapy.

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2022)

Add to Collection

Review Oncology

Antibody-Drug Conjugates as an Emerging Therapy in Oncodermatology

Clara Esnault et al.

Summary: Antibody-drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. However, current targeted therapies or immune checkpoint-blocking antibodies outperform conventional chemotherapy, with proven benefit to survival. Nevertheless, these therapies still have limitations such as primary and acquired resistances as well as adverse events. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology.

CANCERS (2022)

Add to Collection

Article Oncology

Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance

Rachelle Tibbetts et al.

Summary: Neuroblastoma cells universally express GD2, but the degree of anti-GD2 antibody internalization varies among different cell lines, and this internalization is inversely correlated with antibody-dependent cellular cytotoxicity.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Medicine, Research & Experimental

Antibodies to watch in 2021

Helene Kaplon et al.

Summary: The year 2020 saw significant developments in the field of antibody therapeutics, particularly in response to the COVID-19 pandemic. Several antibody products were granted emergency use authorization, and new antibody treatments received first approvals in the US or EU.

MABS (2021)

Add to Collection

Article Oncology

The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Nathan M. Kendsersky et al.

Summary: The study demonstrates significant antitumor activity of the B7-H3-targeting antibody-drug conjugate in pediatric solid tumor PDX models, showing a positive response across various cancer types.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Antibody-Drug Conjugates-A Tutorial Review

Stephanie Baah et al.

Summary: ADCs are a family of targeted therapeutic agents for cancer treatment, with over 80 currently in clinical development and 11 approved by the FDA. They offer enhanced targeting of cancer cells and reduced toxic side effects compared to traditional approaches, making them an attractive prospect in oncology research.

MOLECULES (2021)

Add to Collection

Article Oncology

Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer

Takahiro Ishii et al.

Summary: Despite the limited prognosis of therapeutic advances for metastatic gastric cancer, a new drug, T-DXd, has shown significantly higher objective response rate and longer overall survival in patients with HER2-positive advanced gastric cancer with previous lines of chemotherapy. This new drug has been approved in Japan, and future developments may include new anti-HER2 drugs and treatment strategies incorporating T-DXd with cytotoxic chemotherapy or immune checkpoint inhibitors.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Add to Collection

Article Oncology

Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization

Samantha Buongervino et al.

Summary: In this study, it was found that DNA binding drugs exhibit higher cytotoxicity to neuroblastomas compared to tubulin-binding or DNA topoisomerase 1 inhibiting drugs. The internalization kinetics of antibodies in neuroblastomas correlated significantly with GPC2 cell surface density, while sensitivity to PBD dimers primarily determined the efficacy of corresponding ADC, outweighing the influence of GPC2 cell surface density and antibody internalization.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Chisato M. Yamazaki et al.

Summary: In this study, dual-drug ADCs show promising therapeutic potential for treating heterogeneous breast tumors with minimal toxicity and optimal pharmacokinetic profiles. Compared to co-administration of two single-drug variants, the dual-drug ADC exhibits greater treatment effect and survival benefit in xenograft mouse models representing intratumor HER2 heterogeneity and drug resistance.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Polymer Science

Size-Dependent Biodistribution of Fluorescent Furano-Allocolchicinoid-Chitosan Formulations in Mice

Iuliia Gracheva et al.

Summary: The study aimed to compare the biodistribution of two different formulations of a colchicine derivative in mice. Results showed that encapsulation in chitosan nanoparticles led to more accumulation in liver and spleen, while less in kidney and lungs, suggesting potential benefits for drug redistribution and antitumor accumulation.

POLYMERS (2021)

Add to Collection

Review Health Care Sciences & Services

Breast Cancer Treatments: Updates and New Challenges

Anna Burguin et al.

Summary: Breast cancer, the most frequent cancer diagnosed in women worldwide, can be classified into four molecular subtypes for personalized treatment targeting receptors, but resistance and adverse effects remain challenges. Treatments for TNBC and other subgroups are still not standardized, with emerging approaches like immunotherapy and targeting other metabolic pathways gaining attention.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Review Oncology

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

Brandon M. Bordeau et al.

Summary: The limited efficacy of monoclonal antibody therapies in solid tumors is due to the abnormal vasculature and dense extracellular matrix of tumors, which hinder mAb transport. Strategies to improve mAb uptake in preclinical studies have not yet translated into clinical success.

CANCER BIOLOGY & MEDICINE (2021)

Add to Collection

Review Medicine, Research & Experimental

Targeting cancer with antibody-drug conjugates: Promises and challenges

Alexis Q. Dean et al.

Summary: ADCs are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. While there are several ADCs approved by the FDA and many more in clinical trials, challenges remain in expanding their therapeutic index. Advances in manufacturing technology and new bioconjugation platforms are shaping the future development of ADCs.

MABS (2021)

Add to Collection

Article Oncology

Targets and Antibody Formats for Immunotherapy of Neuroblastoma

Jeong A. Park et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer

Megan Minnix et al.

CANCER MEDICINE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Gangliosides and Neuroblastomas

Cara-Lynne Schengrund

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Review Oncology

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Bassel Nazha et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype

Maxim Sorokin et al.

BIOMEDICINES (2020)

Add to Collection

Article Medicine, Research & Experimental

Involvement of Actin Filaments in the Cytotoxic Effect of GD2-Specific Antibodies

I. I. Doronin et al.

BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE (2019)

Add to Collection

Article Oncology

Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma

Elizabeth R. Butch et al.

CANCER RESEARCH (2019)

Add to Collection

Article Biochemical Research Methods

Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials

Montserrat Carrasco-Triguero et al.

BIOANALYSIS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies

Irina V. Kholodenko et al.

MOLECULES (2019)

Add to Collection

Article Pathology

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

Tatjana Terzic et al.

PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)

Add to Collection

Review Immunology

Neuroblastoma Origin and Therapeutic Targets for Immunotherapy

Irina V. Kholodenko et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2018)

Add to Collection

Article Chemistry, Multidisciplinary

Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates

Matthew R. Levengood et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)

Add to Collection

Article Biochemical Research Methods

Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates

Xiuxia Sun et al.

BIOCONJUGATE CHEMISTRY (2017)

Add to Collection

Article Pharmacology & Pharmacy

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

Aman P. Singh et al.

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2016)

Add to Collection

Article Oncology

Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

Magdalena Dorywalska et al.

MOLECULAR CANCER THERAPEUTICS (2016)

Add to Collection

Article Oncology

Ganglioside GD2 in reception and transduction of cell death signal in tumor cells

Igor I. Doronin et al.

BMC CANCER (2014)

Add to Collection

Article Biochemistry & Molecular Biology

Caspases participation in cell death induced by the GD2-specific antibodies

P. A. Vishnyakova et al.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY (2014)

Add to Collection

Article Immunology

Crosstalk between Human IgG Isotypes and Murine Effector Cells

Marije B. Overdijk et al.

JOURNAL OF IMMUNOLOGY (2012)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

64Cu-p-NH2-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma

Amy L. Vavere et al.

JOURNAL OF NUCLEAR MEDICINE (2012)

Add to Collection

Article Biochemical Research Methods

Tunable Degradation of Maleimide-Thiol Adducts in Reducing Environments

Aaron D. Baldwin et al.

BIOCONJUGATE CHEMISTRY (2011)

Add to Collection

Review Biochemistry & Molecular Biology

Modern Technologies for Creating Synthetic Antibodies for Clinical Application

S. M. Deyev et al.

ACTA NATURAE (2009)

Add to Collection

Article Oncology

Binding activities and antitumor properties of a new Mouse/Human chimeric antibody specific for GD2 ganglioside antigen

Nidia Alvarez-Rueda et al.

CLINICAL CANCER RESEARCH (2007)

Add to Collection

Article Oncology

DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses

E Bolesta et al.

CANCER RESEARCH (2005)

Add to Collection

Article Oncology

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

KJ Hamblett et al.

CLINICAL CANCER RESEARCH (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.